Literature DB >> 26313466

Dissecting the role of epidermal growth factor receptor catalytic activity during liver regeneration and hepatocarcinogenesis.

Judit López-Luque1, Daniel Caballero-Díaz1, Adoración Martinez-Palacián2, César Roncero2, Joaquim Moreno-Càceres1, María García-Bravo3,4,5, Esther Grueso3,4, Almudena Fernández4,6, Eva Crosas-Molist1, María García-Álvaro2, Annalisa Addante2, Esther Bertran1, Angela M Valverde7,8, Águeda González-Rodríguez7,8, Blanca Herrera2, Lluis Montoliu4,6, Teresa Serrano9, Jose-Carlos Segovia3,4,5, Margarita Fernández2, Emilio Ramos10, Aránzazu Sánchez2, Isabel Fabregat1,11.   

Abstract

UNLABELLED: Different data support a role for the epidermal growth factor receptor (EGFR) pathway during liver regeneration and hepatocarcinogenesis. However, important issues, such as the precise mechanisms mediating its actions and the unique versus redundant functions, have not been fully defined. Here, we present a novel transgenic mouse model expressing a hepatocyte-specific truncated form of human EGFR, which acts as negative dominant mutant (ΔEGFR) and allows definition of its tyrosine kinase-dependent functions. Results indicate a critical role for EGFR catalytic activity during the early stages of liver regeneration. Thus, after two-thirds partial hepatectomy, ΔEGFR livers displayed lower and delayed proliferation and lower activation of proliferative signals, which correlated with overactivation of the transforming growth factor-β pathway. Altered regenerative response was associated with amplification of cytostatic effects of transforming growth factor-β through induction of cell cycle negative regulators. Interestingly, lipid synthesis was severely inhibited in ΔEGFR livers after partial hepatectomy, revealing a new function for EGFR kinase activity as a lipid metabolism regulator in regenerating hepatocytes. In spite of these profound alterations, ΔEGFR livers were able to recover liver mass by overactivating compensatory signals, such as c-Met. Our results also indicate that EGFR catalytic activity is critical in the early preneoplastic stages of the liver because ΔEGFR mice showed a delay in the appearance of diethyl-nitrosamine-induced tumors, which correlated with decreased proliferation and delay in the diethyl-nitrosamine-induced inflammatory process.
CONCLUSION: These studies demonstrate that EGFR catalytic activity is critical during the initial phases of both liver regeneration and carcinogenesis and provide key mechanistic insights into how this kinase acts to regulate liver pathophysiology. (Hepatology 2016;63:604-619).
© 2015 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26313466     DOI: 10.1002/hep.28134

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  13 in total

1.  Combined systemic elimination of MET and epidermal growth factor receptor signaling completely abolishes liver regeneration and leads to liver decompensation.

Authors:  Shirish Paranjpe; William C Bowen; Wendy M Mars; Anne Orr; Meagan M Haynes; Marie C DeFrances; Silvia Liu; George C Tseng; Anastasia Tsagianni; George K Michalopoulos
Journal:  Hepatology       Date:  2016-10-01       Impact factor: 17.425

2.  TCPOBOP-Induced Hepatomegaly and Hepatocyte Proliferation are Attenuated by Combined Disruption of MET and EGFR Signaling.

Authors:  Bharat Bhushan; John W Stoops; Wendy M Mars; Anne Orr; William C Bowen; Shirish Paranjpe; George K Michalopoulos
Journal:  Hepatology       Date:  2018-12-31       Impact factor: 17.425

3.  Lgr5+ pericentral hepatocytes are self-maintained in normal liver regeneration and susceptible to hepatocarcinogenesis.

Authors:  Chow Hiang Ang; Shih Han Hsu; Fusheng Guo; Chong Teik Tan; Victor C Yu; Jane E Visvader; Pierce K H Chow; Nai Yang Fu
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-05       Impact factor: 11.205

4.  Attenuating the Epidermal Growth Factor Receptor-Extracellular Signal-Regulated Kinase-Sex-Determining Region Y-Box 9 Axis Promotes Liver Progenitor Cell-Mediated Liver Regeneration in Zebrafish.

Authors:  Juhoon So; Minwook Kim; Seung-Hoon Lee; Sungjin Ko; Daniel A Lee; Hyewon Park; Mizuki Azuma; Michael J Parsons; David Prober; Donghun Shin
Journal:  Hepatology       Date:  2021-04       Impact factor: 17.425

Review 5.  EGFR Signaling in Liver Diseases.

Authors:  Karin Komposch; Maria Sibilia
Journal:  Int J Mol Sci       Date:  2015-12-29       Impact factor: 5.923

Review 6.  BMP Signalling at the Crossroad of Liver Fibrosis and Regeneration.

Authors:  Blanca Herrera; Annalisa Addante; Aránzazu Sánchez
Journal:  Int J Mol Sci       Date:  2017-12-23       Impact factor: 5.923

7.  Ductular reaction correlates with fibrogenesis but does not contribute to liver regeneration in experimental fibrosis models.

Authors:  András Rókusz; Dániel Veres; Armanda Szücs; Edina Bugyik; Miklós Mózes; Sándor Paku; Péter Nagy; Katalin Dezső
Journal:  PLoS One       Date:  2017-04-26       Impact factor: 3.240

8.  Partial Inhibition of HO-1 Attenuates HMP-Induced Hepatic Regeneration against Liver Injury in Rats.

Authors:  Ning He; Jun-Jun Jia; Hai-Yang Xie; Jian-Hui Li; Yong He; Sheng-Yong Yin; Ruo-Peng Liang; Li Jiang; Jing-Feng Liu; Kang-di Xu; Zhi-Hao Zhang; Lin Zhou; Shu-Sen Zheng
Journal:  Oxid Med Cell Longev       Date:  2018-04-15       Impact factor: 6.543

9.  Hypertension and the roles of the 9p21.3 risk locus: Classic findings and new association data.

Authors:  Juan E Gallo; Juan E Ochoa; Helen R Warren; Elizabeth Misas; Monica M Correa; Jaime A Gallo-Villegas; Gabriel Bedoya; Dagnóvar Aristizábal; Juan G McEwen; Mark J Caulfield; Gianfranco Parati; Oliver K Clay
Journal:  Int J Cardiol Hypertens       Date:  2020-09-15

10.  Downregulation of Epidermal Growth Factor Receptor in hepatocellular carcinoma facilitates Transforming Growth Factor-β-induced epithelial to amoeboid transition.

Authors:  Judit López-Luque; Esther Bertran; Eva Crosas-Molist; Oscar Maiques; Andrea Malfettone; Laia Caja; Teresa Serrano; Emilio Ramos; Victoria Sanz-Moreno; Isabel Fabregat
Journal:  Cancer Lett       Date:  2019-08-26       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.